Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression.

**Intervention:** Branched-chain amino acid (BCAA) supplementation — a mixture of leucine, isoleucine, and valine, typically in a 2:1:1 ratio (leucine:isoleucine:valine). Doses ranged from 0.087 g/kg body weight to 0.3 g/kg body weight per day, with most studies using 10–20 g/day split into 2–3 doses.

**Comparators:** Placebo (usually maltodextrin, rice flour, or other isocaloric carbohydrate/protein powder matched for calories and appearance) or no supplementation.

**Outcome measures:**

**Primary:** Creatine kinase (CK) — a blood marker of muscle membrane damage, measured in U/L. Higher CK = more muscle damage.

**Secondary:** Lactate dehydrogenase (LDH) — another muscle damage enzyme. Muscle soreness — subjective rating on a 0–10 visual analogue scale (VAS) or 1–10 Likert scale. Muscle function (e.g., maximal voluntary contraction, jump height) was also assessed in some studies.

**Timing:** Supplementation began either 7 days before exercise (loading phase) or immediately after exercise, and continued for 24–96 hours post-exercise. Blood samples and soreness ratings were taken at baseline, immediately post-exercise, and at 24, 48, 72, and sometimes 96 hours.

**Sample size:** 32 randomised controlled trials, totalling 1,074 participants (range per study: 10 to 80 participants).

**Population:** Healthy, physically active adults aged 18–45 years. Most were male (~75% of participants across studies). All were non-smokers, free from metabolic or musculoskeletal disease, and not taking any other supplements or medications.

**Setting:** University laboratories and sports science research centres. All exercise protocols were supervised.

**Exercise-induced muscle damage (EIMD) protocols:** The most common was downhill running (treadmill at −10% to −15% gradient, 30–60 minutes at 70–80% VO₂max). Others included eccentric leg extensions (3–5 sets of 10–15 reps at 80–120% of 1-rep max), plyometric jumps (10 sets of 10 maximal countermovement jumps), and repeated sprints.

**Creatine kinase (CK):** Venous blood samples, typically analysed via enzymatic colorimetric assay. Normal resting CK is ~50–200 U/L; after muscle damage, it can spike to 1,000–10,000+ U/L depending on the protocol.

**Lactate dehydrogenase (LDH):** Same blood sample, same assay type. Normal range ~100–200 U/L.

**Muscle soreness:** Visual analogue scale (VAS) — a 10 cm line with "no soreness" at 0 and "worst imaginable soreness" at 10. Participants marked their perceived soreness during a standardised movement (e.g., squat, leg extension, or palpation of the quadriceps).

**Muscle function:** Isometric maximal voluntary contraction (MVC) using a dynamometer, or countermovement jump height on a force plate.

**Study design:** This is a systematic review and meta-analysis with meta-regression. The authors searched five databases (PubMed, Scopus, Web of Science, Cochrane Library, SPORTDiscus) for randomised controlled trials published up to January 2024. Two reviewers independently screened titles/abstracts, then full texts. Disagreements were resolved by consensus.

**Inclusion criteria:** (1) Randomised controlled trial (RCT) with a placebo or control group; (2) participants were healthy adults; (3) BCAA supplementation was the sole intervention (no co-supplementation with other amino acids, protein, or creatine); (4) exercise protocol was designed to induce muscle damage (eccentric or high-force); (5) at least one of CK, LDH, or soreness was measured at baseline and at least one post-exercise time point.

**Exclusion criteria:** Studies where BCAA was combined with other supplements (e.g., glutamine, carbohydrate, protein), studies in clinical populations (e.g., liver disease, kidney disease), animal studies, and non-English publications.

**Risk of bias assessment:** Used the Cochrane Risk of Bias 2.0 tool for RCTs. Each study was rated as low risk, some concerns, or high risk across domains: randomisation process, deviations from intended interventions, missing outcome data, measurement of outcome, and selection of reported result.

**Statistical approach:**

Random-effects meta-analysis using restricted maximum likelihood estimation. This assumes the true effect varies across studies (due to different populations, doses, exercise protocols) and gives a more conservative estimate than fixed-effects models.

Effect sizes were calculated as standardised mean differences (SMD) with 95% confidence intervals. SMD is used when different studies measure the same outcome on different scales (e.g., different CK assays or different soreness scales).

Heterogeneity was assessed using I² (percentage of variation across studies due to true differences rather than chance). I² > 50% was considered substantial.

Meta-regression was used to explore whether dose (g/kg body weight), timing (pre-loading vs. post-exercise only), sex, or exercise type explained differences in effect sizes.

Publication bias was assessed using funnel plots and Egger's test.

**What this design can and cannot prove:**

**Can prove:** That BCAA supplementation, on average, reduces muscle damage markers and soreness compared to placebo in healthy adults performing unaccustomed eccentric exercise. The meta-analytic approach pools data across many small studies, increasing statistical power and generalisability.

**Cannot prove:**

**Causality at the individual level:** Meta-analyses show average effects, not individual responses. Some people may respond strongly, others not at all.

**Long-term effects:** Most studies lasted 48–96 hours. No data on chronic supplementation (weeks/months) or training adaptation.

**Mechanism:** The meta-analysis cannot determine *how* BCAA works — whether it reduces muscle damage directly, speeds repair, or simply blunts pain perception.

**Dose-response:** Meta-regression can explore dose effects, but these are observational (across studies, not within studies) and prone to confounding.

**Real-world performance:** Most studies used laboratory-based eccentric protocols, not real training sessions or competitions.

**Major methodological weaknesses flagged by the authors:**

High heterogeneity for CK outcomes (I² = 78%), meaning the effect varied substantially across studies.

Many studies had small sample sizes (n < 20 per group), increasing risk of false positives.

Only 12 of 32 studies reported adequate allocation concealment; 8 had unclear randomisation methods.

Few studies pre-registered their protocols, raising risk of selective outcome reporting.

Industry funding was not reported for most studies, but BCAA supplements are commercially marketed, creating potential conflict of interest.

**Primary outcome — Creatine kinase (CK):**

BCAA supplementation significantly reduced CK levels compared to placebo at 24 hours post-exercise: SMD = −0.64 (95% CI: −0.89 to −0.39, p < 0.001), I² = 78%.

At 48 hours: SMD = −0.71 (95% CI: −0.98 to −0.44, p < 0.001), I² = 74%.

At 72 hours: SMD = −0.55 (95% CI: −0.82 to −0.28, p < 0.001), I² = 65%.

At 96 hours: SMD = −0.42 (95% CI: −0.68 to −0.16, p = 0.002), I² = 58%.

In absolute terms, the weighted mean difference for CK at 48 hours was approximately −350 U/L (range across studies: −150 to −800 U/L). This means BCAA reduced the post-exercise CK spike by roughly 30–40% compared to placebo.

**Secondary outcome — Lactate dehydrogenase (LDH):**

BCAA significantly reduced LDH at 24 hours: SMD = −0.48 (95% CI: −0.72 to −0.24, p < 0.001), I² = 62%.

At 48 hours: SMD = −0.52 (95% CI: −0.78 to −0.26, p < 0.001), I² = 59%.

At 72 hours: SMD = −0.38 (95% CI: −0.61 to −0.15, p = 0.001), I² = 55%.

Absolute reduction was approximately 50–80 U/L (15–25% reduction from placebo).

**Secondary outcome — Muscle soreness (VAS 0–10):**

BCAA significantly reduced soreness at 24 hours: SMD = −0.55 (95% CI: −0.79 to −0.31, p < 0.001), I² = 71%.

At 48 hours: SMD = −0.62 (95% CI: −0.88 to −0.36, p < 0.001), I² = 68%.

At 72 hours: SMD = −0.48 (95% CI: −0.73 to −0.23, p < 0.001), I² = 60%.

On a 0–10 scale, this translates to a reduction of approximately 1.0–1.8 points (e.g., from 6.5 to 4.8 at 48 hours).

**Secondary outcome — Muscle function (MVC or jump height):**

BCAA showed a small but non-significant improvement in muscle function recovery at 48 hours: SMD = 0.28 (95% CI: −0.02 to 0.58, p = 0.07), I² = 45%.

At 72 hours: SMD = 0.22 (95% CI: −0.08 to 0.52, p = 0.15), I² = 40%.

This means BCAA did not reliably speed up strength recovery, despite reducing soreness and damage markers.

**Meta-regression findings:**

**Dose:** Higher BCAA doses (per kg body weight) were associated with larger reductions in CK (β = −0.31, p = 0.04) and soreness (β = −0.28, p = 0.03). The optimal dose appeared to be ≥0.2 g/kg/day (roughly 14–18 g/day for a 70 kg person).

**Timing:** Pre-loading (starting 7 days before exercise) produced slightly larger effects than post-exercise only, but the difference was not statistically significant (p = 0.12).

**Sex:** Only 4 studies included female participants; no significant sex differences were detected, but the analysis was underpowered.

**Exercise type:** Downhill running produced larger CK spikes than eccentric leg extensions, but the relative BCAA effect was similar across protocols.

**Publication bias:** Funnel plot asymmetry was detected for CK at 48 hours (Egger's test p = 0.03), suggesting possible publication bias — small studies with null or negative results may be missing. After adjusting for this using trim-and-fill analysis, the effect remained significant but was reduced by ~15%.

**In plain English:**

**Creatine kinase:** If you do a hard eccentric workout (e.g., downhill running or heavy negatives) and your CK spikes to ~1,200 U/L at 48 hours, taking BCAA would likely bring that down to ~800–850 U/L. That's a meaningful reduction in muscle membrane damage, but still well above normal resting levels.

**Muscle soreness:** If you normally rate your soreness as a 6.5 out of 10 the day after a hard leg day, BCAA might drop that to a 4.8 — roughly a 25–30% reduction. You'll still feel sore, but it will be noticeably less intense.

**Strength recovery:** BCAA does not reliably help you get your strength back faster. If you lose 20% of your squat strength after a damaging workout, BCAA might reduce that loss to 15%, but the evidence is weak and inconsistent.

**Comparison to other interventions:**

The effect of BCAA on soreness is roughly equivalent to taking 1–2 g of omega-3 fatty acids (fish oil) for 4 weeks before exercise, or wearing compression garments for 24 hours post-exercise.

The effect on CK is larger than what's typically seen with tart cherry juice or curcumin, but smaller than what's reported for whole protein supplementation (whey or casein) at similar calorie levels.

**Number needed to treat (NNT):** Not calculable from continuous outcomes, but the authors note that ~60% of BCAA participants reported "meaningful" soreness reduction (≥1.5 points on VAS) compared to ~35% in placebo groups.

**What the authors acknowledge:**

High heterogeneity (I² > 70% for many outcomes) limits confidence in the pooled estimate. The true effect likely varies by dose, timing, exercise type, and individual genetics.

Most studies were small (median n = 20 per study), increasing the risk of small-study effects and overestimation of the true effect.

Few studies reported adequate blinding of participants or assessors. BCAA has a distinct bitter taste, so blinding is difficult — some participants may have guessed their group assignment.

Only 4 of 32 studies included female participants, and none examined menstrual cycle phase. This severely limits generalisability to women.

No studies measured long-term outcomes (e.g., training adaptation, injury risk, or performance over weeks/months).

Publication bias was detected for CK outcomes, meaning the true effect may be smaller than reported.

**Additional limitations a critical reader would note:**

**Industry funding:** While not explicitly reported, many BCAA studies are funded by supplement companies. Industry-funded research tends to show larger effects.

**No standardisation of exercise protocols:** Downhill running, eccentric leg extensions, and plyometrics produce different damage profiles. Pooling them may obscure important differences.

**No control for diet:** BCAA competes with other amino acids for absorption. If participants consumed high-protein meals, the relative benefit of BCAA may be reduced. Most studies did not standardise or report dietary protein intake.

**Short duration:** The longest follow-up was 96 hours. We don't know if BCAA accelerates full recovery (to baseline) or just blunts the peak.

**No mechanistic data:** The meta-analysis cannot distinguish between reduced muscle damage, enhanced repair, or simply a pain-relieving effect (BCAA may influence central fatigue and pain perception via serotonin pathways).

**For someone running their own n=1 experiment:**

### What to test

**Intervention:** BCAA supplement in a 2:1:1 ratio (leucine:isoleucine:valine). Look for a product with no added protein, carbohydrate, or other amino acids.

**Dose:** 0.2–0.3 g/kg body weight per day. For a 70 kg person, that's 14–21 g/day. Split into 2–3 doses (